|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL18BP |
Gene summary for IL18BP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL18BP | Gene ID | 10068 |
| Gene name | interleukin 18 binding protein | |
| Gene Alias | FVH | |
| Cytomap | 11q13.4 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | A0A024R5G2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10068 | IL18BP | P2T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.44e-01 | 0.1177 |
| 10068 | IL18BP | P9T-E | Human | Esophagus | ESCC | 6.03e-07 | 2.54e-01 | 0.1131 |
| 10068 | IL18BP | P11T-E | Human | Esophagus | ESCC | 3.11e-09 | 6.14e-01 | 0.1426 |
| 10068 | IL18BP | P19T-E | Human | Esophagus | ESCC | 4.43e-02 | 3.40e-01 | 0.1662 |
| 10068 | IL18BP | P20T-E | Human | Esophagus | ESCC | 2.14e-03 | 1.09e-01 | 0.1124 |
| 10068 | IL18BP | P24T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.89e-01 | 0.1287 |
| 10068 | IL18BP | P36T-E | Human | Esophagus | ESCC | 7.74e-03 | 2.69e-01 | 0.1187 |
| 10068 | IL18BP | P37T-E | Human | Esophagus | ESCC | 4.64e-04 | 1.34e-01 | 0.1371 |
| 10068 | IL18BP | P52T-E | Human | Esophagus | ESCC | 2.20e-17 | 6.54e-01 | 0.1555 |
| 10068 | IL18BP | P57T-E | Human | Esophagus | ESCC | 3.50e-02 | 7.92e-02 | 0.0926 |
| 10068 | IL18BP | P62T-E | Human | Esophagus | ESCC | 6.26e-06 | 2.66e-01 | 0.1302 |
| 10068 | IL18BP | P75T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.62e-01 | 0.1125 |
| 10068 | IL18BP | P76T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.79e-01 | 0.1207 |
| 10068 | IL18BP | P80T-E | Human | Esophagus | ESCC | 4.15e-08 | 3.94e-01 | 0.155 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
| GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
| GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
| GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
| GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
| GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
| GO:00703018 | Esophagus | ESCC | cellular response to hydrogen peroxide | 68/8552 | 98/18723 | 1.70e-06 | 2.03e-05 | 68 |
| GO:003461220 | Esophagus | ESCC | response to tumor necrosis factor | 149/8552 | 253/18723 | 1.47e-05 | 1.33e-04 | 149 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:007135620 | Esophagus | ESCC | cellular response to tumor necrosis factor | 132/8552 | 229/18723 | 1.69e-04 | 1.11e-03 | 132 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL18BP | SNV | Missense_Mutation | rs370464613 | c.487N>A | p.Val163Ile | p.V163I | O95998 | protein_coding | tolerated(0.57) | benign(0.043) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL18BP | SNV | Missense_Mutation | c.567N>A | p.Ser189Arg | p.S189R | O95998 | protein_coding | tolerated_low_confidence(0.33) | benign(0.062) | TCGA-AZ-6600-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cpt-11 | PD | |
| IL18BP | SNV | Missense_Mutation | c.287N>T | p.Ser96Ile | p.S96I | O95998 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| IL18BP | SNV | Missense_Mutation | novel | c.275N>C | p.Phe92Ser | p.F92S | O95998 | protein_coding | deleterious(0.03) | benign(0.11) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
| IL18BP | SNV | Missense_Mutation | rs768554589 | c.490N>A | p.Val164Ile | p.V164I | O95998 | protein_coding | tolerated(0.51) | benign(0.011) | TCGA-DC-6682-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| IL18BP | SNV | Missense_Mutation | novel | c.76N>A | p.Leu26Ile | p.L26I | O95998 | protein_coding | tolerated(0.48) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL18BP | SNV | Missense_Mutation | rs370464613 | c.487G>A | p.Val163Ile | p.V163I | O95998 | protein_coding | tolerated(0.57) | benign(0.043) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IL18BP | SNV | Missense_Mutation | novel | c.35N>A | p.Ser12Asn | p.S12N | O95998 | protein_coding | tolerated_low_confidence(0.1) | benign(0.025) | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL18BP | SNV | Missense_Mutation | c.166N>T | p.Pro56Ser | p.P56S | O95998 | protein_coding | tolerated(0.35) | benign(0.025) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| IL18BP | SNV | Missense_Mutation | c.484N>T | p.His162Tyr | p.H162Y | O95998 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-E6-A1LZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |